Abstract
Description
The ‘Cardiovascular Partnering Terms and Agreements’ report provides
comprehensive understanding and unprecedented access to the cardiovascular
partnering deals and agreements entered into by the worlds leading healthcare
companies.
The report provides a detailed understanding and analysis of how and why
companies enter cardiovascular partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right to license the licensors cardiovascular technology. These deals
tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This report contains over 2,000 links to online copies of actual
cardiovascular deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners. Contract documents
provide the answers to numerous questions about a prospective partner's
flexibility on a wide range of important issues, many of which will have a
significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of cardiovascular
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in cardiovascular
dealmaking since 2007, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading cardiovascular deals since 2007.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma, and most active of all biopharma companies. Where the deal has an
agreement contract published at the SEC a link provides online access to the
contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of cardiovascular
deals, as well as contract documents available in the public domain. Where
available, each deal title links via Weblink to an online version of the
actual contract document, providing easy access to each contract document on
demand.
Chapter 5 provides a comprehensive and detailed review of cardiovascular
partnering deals signed and announced since 2007, where a contract document is
available in the public domain. The chapter is organized by stage of
development at signing, deal type (collaborative R&D, co-promotion, licensing
etc), technology type and specific therapy focus. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in cardiovascular partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
cardiovascular technologies and products.
Key benefits
‘Cardiovascular Partnering Terms and Agreements’ provides the reader with the following key benefits:
- In-depth understanding of cardiovascular deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 2,000 links to actual cardiovascular deals
entered into by the world's biopharma companies
- Detailed access to actual cardiovascular contracts enter into by the
leading fifty bigpharma companies
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Report scope
‘Cardiovascular Partnering Terms and Agreements’ is intended to provide the
reader with an in-depth understanding and access to cardiovascular trends and
structure of deals entered into by leading companies worldwide.
‘Cardiovascular Partnering Terms and Agreements’ includes:
- Trends in cardiovascular dealmaking in the biopharma industry since 2007
- Analysis of cardiovascular deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life cardiovascular deals
- Access to over 2,000 cardiovascular deal records
- The leading cardiovascular deals by value since 2007
- Most active cardiovascular dealmakers since 2007
- The leading cardiovascular partnering resources
In ‘Cardiovascular Partnering Terms and Agreements’, the available contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
The ‘Cardiovascular Partnering Terms and Agreements’ report provides
comprehensive access to available deals and contract documents for over 2,700
cardiovascular deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise cardiovascular rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in cardiovascular dealmaking
- 2.1. Introduction
- 2.2. Cardiovascular partnering over the years
- 2.3. Bigpharma cardiovascular dealmaking activity
- 2.4. Bigpharma not active in cardiovascular
- 2.5. Cardiovascular partnering by deal type
- 2.6. Cardiovascular partnering by industry sector
- 2.7. Cardiovascular partnering by stage of development
- 2.8. Cardiovascular partnering by technology type
- 2.9. Cardiovascular partnering by cardiovascular indication
- 2.10. Average deal terms for cardiovascular
- 2.10.1. Cardiovascular headline values
- 2.10.2. Cardiovasular upfront payments
- 2.10.3. Cardiovascular milestone payments
- 2.10.4. Cardiovascular royalty rates
Chapter 3 - Leading cardiovascular deals
- 3.1. Introduction
- 3.2. Top cardiovascular deals by value
- 3.3. Top cardiovascular deals involving bigpharma
Chapter 4 - Bigpharma cardiovascular deals
- 4.1. Introduction
- 4.2. How to use bigpharma partnering deals
- 4.3. Bigpharma cardiovascular partnering company profiles
- Abbott
- Actavis
- Actelion
- Amgen
- Aspen Pharmacare
- Astellas
- AstraZeneca
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Eisai
- Eli Lilly
- Forest Laboratories
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Lundbeck
- Menarini
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novartis
- Otsuka
- Pfizer
- Roche
- Sanofi
- Servier
- Shire
- Takeda
- Teva
- Valeant
- Warner Chilcott
- Watson
Chapter 5 - Cardiovascular partnering contracts directory
- 5.1. Introduction
- 5.2. By deal type
- Asset purchase
- Assignment
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Joint venture
- Licensing
- Litigation
- Loan
- Manufacturing
- Manufacturing - OEM
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- Warranty
- 5.3. By stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- Formulation
- 5.4. By technology type
- Assays
- Biodefense
- Bioinformatics
- Biological compounds
- Biomarkers
- Blood products
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- Drug delivery
- Enabling technology
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Implant
- Natural product
- Oligonucleotide
- Orphan drug
- Packaging
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Recombinant DNA
- Regenerative medicine
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Software tools
- Stem cells
Chapter 6 - Cardiovascular dealmaking by indication
- 6.1. Introduction
- 6.2. Deals by therapeutic indication
- Cardiovascular
- Abdominal aortic aneurysm
- Angina
- Arrhythmia
- Atrial fibrillation
- Long QT syndrome
- Supraventricular Tachycardia
- Atherosclerosis
- Cardiogenic shock
- Cardiomyopathy (heart muscle disease)
- Chest pain
- Congenital heart disease
- Congestive heart failure
- Coronary artery disease
- Ductus arteriosus
- Hypercholesterolemia
- Hypertension
- Intermittent claudication
- Ischemic heart disease
- Limb ischemia
- Myocardial Infarction
- Oedema (excess fluid)
- Peripheral arterial disease
- Thrombus (blood clot)
- Restenosis
- Varicose veins
Chapter 7 - Partnering resource center
- 7.1. Online partnering
- 7.2. Partnering events
- 7.3. Further reading on dealmaking
Appendices
- Appendix 1 - Directory of cardiovascular deals by company A-Z 2007-2012
- Appendix 2 - Directory of cardiovascular deals by deal type 2007-2012
- Appendix 3 - Directory of cardiovascular deals by stage of development
2007-2012
- Appendix 4 - Directory of cardiovascular deals by technology type 2007-2012
- Appendix 5 - Deal type definitions
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Cardiovascular partnering since 2007
- Figure 2: Bigpharma - top 50 - cardiovascular deals 2007 to 2012
- Figure 3: Bigpharma cardiovascular deal frequency - 2007 to 2012
- Figure 4: Inactive bigpharma in cardiovascular 2007-2012
- Figure 5: Cardiovascular partnering by deal type since 2007
- Figure 6: Cardiovascular partnering by industry sector since 2007
- Figure 7: Cardiovascular partnering by stage of development since 2007
- Figure 8: Cardiovascular partnering by technology type since 2007
- Figure 9: Cardiovascular partnering by cardiovascular target since 2007
- Figure 10: Cardiovascular deals with a headline value
- Figure 11: Cardiovasular deal headline value distribution, US$million -
discovery stage
- Figure 12: Cardiovasular deal headline value distribution, US$million -
preclinical stage
- Figure 13: Cardiovasular deal headline value distribution, US$million -
phase I stage
- Figure 14: Cardiovasular deal headline value distribution, US$million -
phase II stage
- Figure 15: Cardiovasular deal headline value distribution, US$million -
phase III stage
- Figure 16: Cardiovasular deal headline value distribution, US$million -
regulatory stage
- Figure 17: Cardiovasular deal headline value distribution, US$million -
marketed stage
- Figure 18: Summary median headline value by stage of development, 2007-2012
- Figure 19 Cardiovasular deals with upfront payment values
- Figure 20: Cardiovascular deal upfront payment distribution, US$million -
discovery stage
- Figure 21: Cardiovascular deal upfront payment distribution, US$million -
preclinical stage
- Figure 22: Cardiovascular deal upfront payment distribution, US$million -
phase I stage
- Figure 23: Cardiovascular deal upfront payment distribution, US$million -
phase II stage
- Figure 24: Cardiovascular deal upfront payment distribution, US$million -
phase III stage
- Figure 25: Cardiovascular deal upfront payment distribution, US$million -
regulatory stage
- Figure 26: Cardiovascular deal upfront payment distribution, US$million -
marketed stage
- Figure 27: Summary median upfront payments by stage of development,
2007-2012
- Figure 28: Cardiovascular deals with milestone payments
- Figure 29: Cardiovascular deal milestone distribution, US$million -
discovery stage
- Figure 30: Cardiovascular deal milestone distribution, US$million -
preclinical stage
- Figure 31: Cardiovascular deal milestone distribution, US$million - phase
I stage
- Figure 32: Cardiovascular deal milestone distribution, US$million - phase
II stage
- Figure 33: Cardiovascular deal milestone distribution, US$million - phase
III stage
- Figure 34: Cardiovascular deal milestone distribution, US$million -
regulatory stage
- Figure 35: Cardiovascular deal milestone distribution, US$million -
marketed stage
- Figure 36: Cardiovascular deals with royalty rates, %
- Figure 37: Cardiovascular deal royalty rate distribution, US$million -
discovery stage
- Figure 38: Cardiovascular deal royalty rate distribution, US$million -
preclinical stage
- Figure 39: Cardiovascular deal royalty rate distribution, US$million -
phase I stage
- Figure 40: Cardiovascular deal royalty rate distribution, US$million -
phase II stage
- Figure 41: Cardiovascular deal royalty rate distribution, US$million -
phase III stage
- Figure 42: Cardiovascular deal royalty rate distribution, US$million -
regulatory stage
- Figure 44: Summary median royalty rate by stage of development, 2007-2012
- Figure 45: Top cardiovascular deals by value since 2007
- Figure 46: Top cardiovascular deals signed by bigpharma value since 2007
- Figure 47: Online partnering resources
- Figure 48: Forthcoming partnering events
Cardiovascular Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited in January 31, 2013. This report consists of 769 Pages and the price starts from US $ 2695.
The contents of this page may be different from the latest version. Please contact us for details.
